The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Sleepiness at the wheel is a significant contributing factor to motor vehicle accidents. A new analysis published in ...

Sleepiness at the wheel is a significant contributing factor to motor vehicle accidents. A new analysis published in ...

Insiya Klapper, who lives in the Capital Region, has experienced a transformative year, shedding 60 pounds with the help of the GLP-1 medic ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Read More: Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs ...

Goldman has a buy rating and $325.40 price target on CSL's shares. This implies potential upside of 19% for investors over ...

Tirzepatide, the main ingredient in Mounjaro and Zepbound, is no longer in shortage, according to the U.S. Food and Drug Administration. Compounded copycat drugs containing tirzepatide ...

This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...

In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Is Eli Lilly a good stock to buy on the dip? On ...

The FDA approved Zepbound (tirzepatide) as the first prescription medication specifically for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. People taking Zepbound lost ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.